Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid. Issue 5 (18th January 2022)

• Record Type: Journal Article
• Authors: Klafki, Hans‐Wolfgang; Wirths, Oliver; Mollenhauer, Brit; Liepold, Thomas; Rieper, Petra; Esselmann, Hermann; Vogelgsang, Jonathan; Wiltfang, Jens; Jahn, Olaf
• Is Part Of: Journal of neurochemistry. Volume 160:Issue 5(2022)
• Page Start: 578
• Page End: 589
• Publication Date: 2022-01-18
• Subjects: Alzheimer's disease -- biomarker -- cerebrospinal fluid -- immunoassay -- immunoprecipitation -- mass spectrometry; Neurochemistry -- Periodicals; 616.8042
• DOI: 10.1111/jnc.15571
• Languages: English
• ISSNs: 0022-3042

Abstract

Abstract: Neurochemical biomarkers can support the diagnosis of Alzheimer's disease and may facilitate clinical trials. In blood plasma, the ratio of the amyloid‐β (Aβ) peptides Aβ−3–40/Aβ1–42 can predict cerebral amyloid‐β pathology with high accuracy (Nakamura et al., 2018). Whether or not Aβ−3–40 (aka. amyloid precursor protein (APP) 669–711) is also present in cerebrospinal fluid (CSF) is not clear. Here, we investigated whether Aβ−3–40 can be detected in CSF and to what extent the CSF Aβ−3–40/Aβ42 ratio is able to differentiate between individuals with or without amyloid‐β positron emission tomography (PET) evidence of brain amyloid. The occurrence of Aβ−3–40 in human CSF was assessed by immunoprecipitation followed by mass spectrometry. For quantifying the CSF concentrations of Aβ−3–40 in 23 amyloid PET‐negative and 17 amyloid PET‐positive subjects, we applied a sandwich‐type immunoassay. Our findings provide clear evidence of the presence of Aβ−3–40 and Aβ−3–38 in human CSF. While there was no statistically significant difference in the CSF concentration of Aβ−3–40 between the two diagnostic groups, the CSF Aβ−3–40/Aβ42 ratio was increased in the amyloid PET‐positive individuals. We conclude that Aβ−3–40 appears to be a regular constituent of CSF and may potentially serve to accentuate the selective decrease in CSF Aβ42 in Alzheimer's disease. Abstract : Cerebral amyloid‐β pathology can be predicted by the Aβ−3–40/Aβ1–42 peptide ratio in blood plasma (Nakamura et al., 2018, Nature 554, 249). However, it is still unclear whether Aβ−3–x peptides occur in cerebrospinal fluid (CSF). By immunoprecipitation‐mass spectrometry (IP‐MS), we show that Aβ−3–40 and Aβ−3–38 are regular constituents of CSF. The CSF Aβ−3–40/Aβ42 ratio, measured with a sandwich immunoassay, was found to be increased in individuals with positron emission tomography (PET) evidence of brain amyloid. Thus, CSF Aβ−3–40 may serve to accentuate the selective decrease in CSF Aβ42 in Alzheimer's disease.